Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.

Autor: Cooper N; Imperial College Healthcare NHS Trust, London, UK., Scully M; Haematology Programme, NIHR UCLH/UCL BRC, London, UK., Percy C; University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.; Queen Elizabeth Hospital, Birmingham, UK., Nicolson PLR; University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.; HaemSTAR, Torquay, UK., Lowe G; University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.; Queen Elizabeth Hospital, Birmingham, UK., Bagot CN; Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde NHS Board, Glasgow, UK., Thachil J; Manchester University Hospital NHS Foundation Trust, Manchester, UK., Grech H; Royal Berkshire Hospital NHS Foundation Trust, Reading, UK., Nokes T; University Hospitals Plymouth NHS Trust, Plymouth, UK., Hill QA; Leeds Teaching Hospitals NHS Trust, Leeds, UK., Bradbury C; University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Talks K; Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Dutt T; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Evans G; East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Kent, UK., Pavord S; Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK., Wexler S; Royal United Hospitals Bath NHS Foundation Trust, Bath, UK., Charania A; Imperial College Healthcare NHS Trust, London, UK., Collington SJ; Novartis Pharmaceuticals UK Limited, London, UK., Ervin A; Novartis Pharmaceuticals UK Limited, London, UK., Ramscar N; Novartis Pharmaceuticals UK Limited, London, UK., Provan D; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Jun; Vol. 204 (6), pp. 2442-2452. Date of Electronic Publication: 2024 Mar 01.
DOI: 10.1111/bjh.19345
Abstrakt: Few studies have reported the real-world use of both romiplostim and eltrombopag in immune thrombocytopenia (ITP). TRAIT was a retrospective observational study aimed to evaluate the platelet responses and adverse effects associated with the use of these thrombopoietin receptor agonists (TPO-RAs) in adult patients with ITP in the United Kingdom. Of 267 patients (median age at diagnosis, 48 years) with ITP (primary ITP [n = 218], secondary ITP [n = 49]) included in the study, 112 (42%) received eltrombopag and 155 (58%) received romiplostim as the first prescribed TPO-RA. A platelet count ≥30 × 10 9 /L was achieved in 89% of patients with the first TPO-RA treatments, while 68% achieved a platelet count ≥100 × 10 9 /L. Treatment-free response (TFR; platelet count ≥30 × 10 9 /L, 3 months after discontinuing treatment) was achieved by 18% of the total patients. Overall, 61 patients (23%) switched TPO-RAs, most of whom achieved platelet counts ≥30 × 10 9 /L with the second TPO-RA (23/25 who switched from eltrombopag to romiplostim [92%]; 28/36 who switched from romiplostim to eltrombopag [78%]). TFR was associated with secondary ITP, early TPO-RA initiation after diagnosis, the presence of comorbidity and no prior splenectomy or treatment with steroids or mycophenolate mofetil. Both TPO-RAs had similar efficacy and safety profiles to those reported in clinical studies.
(© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: